Cargando…

Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade

BACKGROUND: Though immune checkpoint blockade (ICB) against PD-1 has shown success in the treatment of lung cancer, not all patients respond. We have previously shown that adoptive transfer of double negative T (DNT) cells expanded from healthy donors can target leukemia but their role in treating e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Linan, Ly, Dalam, Wang, Si-si, Lee, Jong Bok, Kang, Hyeonjeong, Xu, Hao, Yao, Junlin, Tsao, Ming-sound, Liu, Wei, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413451/ https://www.ncbi.nlm.nih.gov/pubmed/30857561 http://dx.doi.org/10.1186/s13046-019-1126-y

Ejemplares similares

Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy
por: Chen, Branson, et al.
Publicado: (2018)

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15
por: Yao, Junlin, et al.
Publicado: (2019)

Directed Evolution of the Transcriptional Regulator DntR: Isolation of Mutants with Improved DNT-Response
por: Lönneborg, Rosa, et al.
Publicado: (2012)

Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma
por: Ly, Dalam, et al.
Publicado: (2021)

Neuron-Type Specific Functions of DNT1, DNT2 and Spz at the Drosophila Neuromuscular Junction
por: Sutcliffe, Ben, et al.
Publicado: (2013)

Cytotoxicity of Dinitrotoluenes (2,4-DNT, 2,6-DNT) to MCF-7 and MRC-5 Cells
por: Ishaque, Ali B., et al.
Publicado: (2005)

Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism
por: Wang, Miao, et al.
Publicado: (2022)

Development and validation of the Diabetes Numeracy Test (DNT)
por: Huizinga, Mary Margaret, et al.
Publicado: (2008)

DNT Cell-based Immunotherapy: Progress and Applications
por: Li, Yingrui, et al.
Publicado: (2020)

Dnt1 acts as a mitotic inhibitor of the spindle checkpoint protein dma1 in fission yeast
por: Wang, Yamei, et al.
Publicado: (2012)

Structural basis of transcription factor YhaJ for DNT detection
por: Kim, Myeongbin, et al.
Publicado: (2023)

Recovery from spindle checkpoint-mediated arrest requires a novel Dnt1-dependent APC/C activation mechanism
por: Bai, Shuang, et al.
Publicado: (2022)

Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer
por: Wang, Dennis, et al.
Publicado: (2019)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods
por: Bal-Price, Anna, et al.
Publicado: (2018)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

State-of-Art of Cellular Therapy for Acute Leukemia
por: Lee, Jong-Bok, et al.
Publicado: (2021)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Improving the Chemical Selectivity of an Electronic Nose to TNT, DNT and RDX Using Machine Learning
por: Gradišek, Anton, et al.
Publicado: (2019)

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
por: Wei, Spencer C., et al.
Publicado: (2019)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
por: Li, Si-Qi, et al.
Publicado: (2022)

Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes
por: Fritsche, Ellen, et al.
Publicado: (2018)

Enhancing DNT Detection by a Bacterial Bioreporter: Directed Evolution of the Transcriptional Activator YhaJ
por: Elad, Tal, et al.
Publicado: (2022)

Neurodevelopmental toxicity assessment of flame retardants using a human DNT in vitro testing battery
por: Klose, Jördis, et al.
Publicado: (2021)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
por: Luo, Fan, et al.
Publicado: (2019)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fkekpcl5ccdodu33mir902qmdc